设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至[email protected]

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:中国医师协会
总编辑(兼编辑部主任):

杨秋
副总编辑:魏永祥、张运、

罗毅、谭学瑞、唐来坤、

王喜艳

编辑部副主任:杨水霞
邮发代号:80-528
定价:12.00元
全年:144.00元
Email:[email protected]
电话(传真):010-64428528;
010-64456116(总编室)

                  

过刊目录

2018 年第 10 期 第 13 卷

双丹颗粒对冠状动脉粥样硬化性心脏病患者西雅图心绞痛量表评分和Adropin蛋白水平的影响

Effect of Shuangdan granules on Seattle Angina Questionaire score and Adropin protein in patients with coronary atherosclerotic heart disease

作者:张俊萍孟庆斌张新宇张红朵刘静张恒利武娟王艾萍刘富强

英文作者:

单位:714200陕西省华阴市人民医院内科(张俊萍、孟庆斌、张新宇、张红朵、刘静、张恒利、武娟、王艾萍);710061西安,陕西省人民医院心内科(刘富强)

英文单位:

关键词:冠状动脉粥样硬化性心脏病;双丹颗粒;西雅图心绞痛量表;Adropin蛋白

英文关键词:

  • 摘要:
  • 【摘要】

    【摘要】目的    探讨双丹颗粒对冠状动脉粥样硬化性心脏病(冠心病)患者西雅图心绞痛量表评分和Adropin蛋白水平的影响。方法    选取2016年5月至2017年12月在陕西省人民医院及华阴市人民医院就诊的冠心病患者60例,应用随机数字表法分为2组,各30例。对照组接受标准冠心病二级预防药物治疗,观察组在对照组治疗基础上加服双丹颗粒治疗。比较2组患者治疗前和治疗5周后血脂、血肌酐、尿酸、Adropin蛋白水平和西雅图心绞痛量表(SAQ)评分的变化。结果    2组患者治疗前后血肌酐和血尿酸水平比较差异均无统计学意义(均P>0.05)。治疗前,2组患者血脂水平比较差异均无统计学意义(均 P>0.05)。治疗5周后,2组患者总胆固醇、三酰甘油、低密度脂蛋白胆固醇水平均低于治疗前,高密度脂蛋白胆固醇水平均高于治疗前,差异均有统计学意义(均P<0.05);但组间比较差异均无统计学意义(均P>0.05)。治疗前,2组患者血清Adropin蛋白水平和SAQ评分比较差异均无统计学意义(均P>0.05)。治疗5周后2组患者的Adropin蛋白水平和SAQ评分均高于治疗前,且观察组高于对照组[(439±35)ng/L比(356±47)ng/L、(70±10)分比(56±9)分],差异均有统计学意义(均P<0.05)。结论    冠心病二级预防药物治疗与联合双丹颗粒治疗均能显著降低冠心病患者的血脂水平、升高Adropin蛋白水平,并显著增加SAQ评分,但联合双丹颗粒治疗对Adropin蛋白水平和SAQ评分的改善更大。

  • 【Abstract】Objective    To investigate the effect of Shuangdan granules on the score of Seattle Angina Questionaire(SAQ) and the level of Adropin protein in patients with coronary atherosclerotic heart disease(CHD). Methods    Sixty CHD patients were enrolled from May 2016 to December 2017 in Shaanxi Provincial People′s Hospital and Huayin People′s Hospital. They were randomly divided into control group and observation group, with 30 cases in each group. The control group had medication therapy according to the secondary prevention standards of CHD. The observation group took Shuangdan granules on the basis of control group. Both groups were treated for 5 weeks. Blood lipid, creatinine, uric acid, Adropin protein and SAQ score were analyzed. Results    Levels of serum creatinine and uric acid showed no significant difference between groups before and after treatment(P>0.05). Before treatment, blood lipid levels had no significant difference between groups(P>0.05). After treatment, total cholesterol, triglyceride and low density lipoprotein cholesterol were significantly lower and high density lipoprotein cholesterol was significantly higher than those before treatment in both groups(P<0.05); there was no significant difference between the two groups(P>0.05). Before treatment, serum Adropin protein level and SAQ score showed no significant difference between groups(P>0.05). After treatment, serum Adropin protein level and SAQ score were significantly higher than those before treatment in both groups; serum Adropin protein level and SAQ score in the observation group were significantly higher than those in the control group[(439±35)ng/L vs (356±47)ng/L, (70±10) vs (56±9)](P<0.05). Conclusion    Shuangdan granules combined with CHD secondary prevention drugs can effectively reduce blood lipid, increase Adropin protein level and SAQ score.

copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029
网址:www.chinamedicinej.com Email: [email protected]
当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱[email protected]
京ICP备18043517号







安卓


苹果

关闭